P. Levy (Grenoble, France), M. Bonsignore (Palermo, Italy)
Erythrocyte glycolysis in severe obstructive sleep apnea (OSA)
P. Panagou, G. Papatheodorou, M. Karaiskou, S. Tsipra, C. Mermingis, K. Psathakis, K. Tsintiris (Athens, Greece)
|  |
Hypoxic stress in obstructive sleep apnea syndrome (OSAS) activates invasive ability of monocytes
S. Tamaki, M. Yamauchi, A. Fukuoka, K. Makinodan, K. Tomoda, M. Yoshikawa, H. Kimura (Kashihara, Japan)
| |
Rapid fall of brain-derived neurotrophic factor (BDNF) serum and plasma levels following sleep apnea treatment
R. Staats, P. Stoll, J. C. Virchow, M. Lommatzsch (Rostock, Germany)
| |
Real condition driving performance in obstructive sleep apnoea syndrome (OSAS)
S. Mazza, J. Pepin, E. Rauch, B. Naegele, C. Deschaux, P. Levy (Grenoble, France)
| |
Non-arteritic anterior ischemic optic neuropathy (NAION) is nearly systematically associated with sleep apnoea
K. Palombi, E. Renard, P. Levy, J. P. Romanet, J. L. Pepin (Grenoble, France)
| |
Selective activation of pro-inflammatory cytokines in obstructive sleep apnoea syndrome and impact of CPAP
S. Ryan, M. Ryan, C. T. Taylor, W. T. McNicholas (Dublin, Ireland)
| |
Exhaled breath markers in patients with obstructive sleep apnea (OSA): baseline assessment and the impact of treatment with nasal continuous positive airway pressure
M. Agrafiotis, M. Petrosyan, E. Perraki, N. Rovina, D. Simoes, E. Dima, E. Vagiakis, C. Roussos, C. Gratziou (Athens, Greece)
| |
Brain natriuretic peptide levels in the obstructive sleep apnoea/hypopnoea syndrome
K. Nagaoka, T. Akahoshi, S. Kawahara, N. Nomura, K. Katsura, T. Akashiba, T. Horie (Tokyo, Japan)
| |
24-hour intra-ocular pressure (IOP) course in obstructive sleep apnea (OSA) and effect of CPAP
S. Kiekens, V. De Groot, M. J. Tassignon, W. A. De Backer, J. A. Verbraecken (Edegem, Belgium)
| |
Obstructive sleep apnea is associated with an increased risk of occupational injuries and reduced work productivity
A. T. Mulgrew, J. Fleetham, J. M. Fitzgerald, N. Fox, R. Cheema, C. Marra, C. F. Ryan, N. T. Ayas (Vancouver, Canada)
| |
Nitric oxide in airways of patients with obstructive sleep apnea
G. E. Carpagnano, O. Resta, R. Sabato, M. G. Cagnazzo, I. Ventura, G. Cocuzza, M. P. Foschino Barbaro (Foggia, Bari, Italy)
| |
C-reactive protein levels in obstructive sleep apnea syndrome
F. Kapsimalis, G. Varouchakis, A. Manousaki, D. Nikita, K. Gourgoulianis (Athens, Larissa, Greece)
| |
Plasma total antioxidant status in obstructive sleep apnea men
E. Wysocka, S. Cofta, J. Gozdzik, L. Torlinski, T. Piorunek, A. Nowicka (Pozna, Poland)
| |
C-reactive protein (CRP) levels in obese patients with obstructive sleep apnea (OSA)
R. Sabato, P. Bonfitto, I. Ventura, T. Giliberti, A. DePalo, M. P. Foschino Barbaro (Foggia, Italy)
| |
Lipid peroxides, superoxide dismutase and circulating IL-8 and GCP-2 in patients with severe obstructive sleep apnea
M. A. AlZoghaibi, A. S. BaHammam (Riyadh, Saudi Arabia)
| |
The influence of short-term therapy of continous positive airway pressure (CPAP) on exhaled nitric oxide concentration (FENO) in patients with obstructive sleep apnea (OSA)
T. Przybylowski, P. Bielicki, M. Kumor, K. Hildebrand, R. Chazan (Warsaw, Poland)
| |
Evaluation of long-term effect of continuous positive airway pressure (CPAP) therapy on reduction of high sensitivity C-reactive protein (HSCRP) for patients with obstructive sleep apnea syndrome (OSAS)
H. Ohba, N. Okimoto, Y. Honda, T. Kurihara, K. Yamato, K. Osaki (Okayama city, Japan)
| |
Dipeptidyl peptidase IV and aminopeptidase N activity in children with sleep apnea
M. D. Stankovic, V. Avramovic (Nis, Serbia And Montenegro)
| |